Skin autofluorescence as proxy of tissue AGE accumulation is dissociated from SCORE cardiovascular risk score, and remains so after 3 years

Clin Chem Lab Med. 2014 Jan 1;52(1):121-7. doi: 10.1515/cclm-2012-0825.

Abstract

Background: Skin autofluorescence (SAF), as a proxy of AGE accumulation, is predictive of cardiovascular (CVD) complications in i.a. type 2 diabetes mellitus and renal failure, independently of most conventional CVD risk factors. The present exploratory substudy of the Groningen Overweight and Lifestyle (GOAL)-project addresses whether SAF is related to Systematic COronary Risk Evaluation (SCORE) risk estimation (% 10-year CVD-mortality risk) in overweight/obese persons in primary care, without diabetes/renal disease, and if after 3-year treatment of risk factors (change in, Δ) SAF is related to ΔSCORE.

Methods: In a sample of 65 participants from the GOAL study, with a body mass index (BMI) >25-40 kg/m2, hypertension and/or dyslipidemia, but without diabetes/renal disease, SAF and CVD risk factors were measured at baseline, and after 3 years of lifestyle and pharmaceutical treatment.

Results: At baseline, the mean SCORE risk estimation was 3.1±2.6%, mean SAF 2.04±0.5AU. In multivariate analysis SAF was strongly related to age, but not to other risk factors/SCORE. After 3 years ΔSAF was 0.34±0.45 AU (p<0.001). ΔSAF was negatively related to Δbodyweight but not to ΔSCORE%, or its components. At follow-up, SAF was higher in 11 patients with a history of CVD compared to 54 persons without CVD (p=0.002).

Conclusions: Baseline and 3-year-Δ SAF are not related to (Δ)SCORE, or its components, except age, in the studied population. ΔSAF was negatively related to Δweight. As 3-year SAF was higher in persons with CVD, these results support a larger study on SAF to assess its contribution to conventional risk factors/SCORE in predicting CVD in overweight persons with low-intermediate cardiovascular risk.

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Anticholesteremic Agents / therapeutic use
  • Antihypertensive Agents / therapeutic use
  • Body Mass Index
  • Cardiovascular Diseases / etiology*
  • Cardiovascular Diseases / metabolism
  • Dyslipidemias / complications
  • Dyslipidemias / metabolism
  • Female
  • Follow-Up Studies
  • Glycation End Products, Advanced / metabolism*
  • Humans
  • Hypertension / complications
  • Hypertension / drug therapy
  • Hypertension / metabolism
  • Life Style
  • Male
  • Middle Aged
  • Risk Factors
  • Skin / metabolism*
  • Time Factors

Substances

  • Anticholesteremic Agents
  • Antihypertensive Agents
  • Glycation End Products, Advanced